NasdaqCM:PMD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Psychemedics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PMD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.0%

PMD

-1.5%

US Healthcare

-3.1%

US Market


1 Year Return

-50.2%

PMD

16.7%

US Healthcare

12.7%

US Market

Return vs Industry: PMD underperformed the US Healthcare industry which returned 16.7% over the past year.

Return vs Market: PMD underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

PMDIndustryMarket
7 Day-3.0%-1.5%-3.1%
30 Day-3.8%-5.4%-2.9%
90 Day-15.7%1.5%8.2%
1 Year-48.2%-50.2%18.3%16.7%15.3%12.7%
3 Year-72.3%-75.7%26.0%20.5%37.8%28.5%
5 Year-44.9%-55.1%55.9%44.9%90.9%69.4%

Price Volatility Vs. Market

How volatile is Psychemedics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Psychemedics undervalued compared to its fair value and its price relative to the market?

1.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PMD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: PMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PMD is good value based on its PB Ratio (1.8x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is Psychemedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Psychemedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Psychemedics performed over the past 5 years?

-7.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PMD is currently unprofitable.

Growing Profit Margin: PMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PMD is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.

Accelerating Growth: Unable to compare PMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: PMD has a negative Return on Equity (-14.81%), as it is currently unprofitable.


Next Steps

Financial Health

How is Psychemedics's financial position?


Financial Position Analysis

Short Term Liabilities: PMD's short term assets ($9.8M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: PMD's short term assets ($9.8M) exceed its long term liabilities ($8.6M).


Debt to Equity History and Analysis

Debt Level: PMD's debt to equity ratio (32.1%) is considered satisfactory.

Reducing Debt: PMD's debt to equity ratio has reduced from 46.2% to 32.1% over the past 5 years.

Debt Coverage: PMD's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if PMD's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Psychemedics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PMD is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

21.7yrs

Average management tenure


CEO

Raymond Kubacki (75 yo)

29.67yrs

Tenure

US$736,800

Compensation

Mr. Raymond C. Kubacki has been the President and Chief Executive Officer at Psychemedics Corp., since July 1991. Prior to joining Psychemedics Corp., Mr. Kubacki served as Vice President National Accounts ...


CEO Compensation Analysis

Compensation vs Market: Raymond's total compensation ($USD736.80K) is about average for companies of similar size in the US market ($USD601.89K).

Compensation vs Earnings: Raymond's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Raymond Kubacki
Chairman29.67yrsUS$736.80k3.19%
$ 795.5k
Charles Doucot
Executive Vice President0.67yrUS$436.50k0.0091%
$ 2.3k
Michael Schaffer
Vice President of Laboratory Operations21.67yrsUS$349.80k0.39%
$ 96.0k
Werner Baumgartner
42.67yrsno datano data
Annette Baumgartner
42.67yrsno datano data
Neil Lerner
VP of Finance9.33yrsUS$271.67k0.22%
$ 55.2k
James Abely
VP & General Counsel4.08yrsno datano data
Patrick Kinney
Secretaryno datano datano data

21.7yrs

Average Tenure

64.5yo

Average Age

Experienced Management: PMD's management team is seasoned and experienced (21.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Raymond Kubacki
Chairman29.67yrsUS$736.80k3.19%
$ 795.5k
A. Allen
Independent Director5yrsUS$118.08k0.023%
$ 5.8k
Walter Tomenson
Independent Director21.67yrsUS$118.08k0.57%
$ 141.6k
Fred Weinert
Independent Director29.67yrsUS$334.28k2.44%
$ 609.2k
Harry Connick
Independent Director17yrsUS$119.43k0.92%
$ 229.4k

17.0yrs

Average Tenure

75yo

Average Age

Experienced Board: PMD's board of directors are seasoned and experienced ( 17 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Psychemedics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Psychemedics Corporation
  • Ticker: PMD
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$24.927m
  • Shares outstanding: 5.53m
  • Website: https://www.psychemedics.com

Number of Employees


Location

  • Psychemedics Corporation
  • 289 Great Road
  • Suite 200
  • Acton
  • Massachusetts
  • 1720
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PMDNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1987

Biography

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 06:15
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.